clinical trial · NCT07039669
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·phase3·recruiting·n = 594
Pulmonary Disease, Chronic Obstructive (COPD)611Placebo
brief summary
The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
started
Jul 16, 2025
primary completion
Sep 1, 2028
completion
Nov 1, 2028
last updated
Nov 18, 2025
detailed description
The maximum study duration was 66 weeks per participants, including a screening period of up to 6 weeks, a 52-week randomized treatment period, and a 8-week follow-up period.
official title
A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol